AACR 2023 | PKMYT1 kinase as a target in TNBC with LMW-E

Khandan Keyomarsi, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses PKMYT1 kinase as a potential target for triple negative breast cancers with low molecular weight cyclin E (LMW-E) expression. RP-6306, a first in-class inhibitor of PKMYT1 kinase was found to be efficacious in cells overexpressing LMW-E, which is known to increase DNA damage and apoptosis. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.